Healthcare >> CEO Interviews >> September 30, 1999
STEVEN H. HOLTZMAN has been the Chief Business Officer of Millennium
Pharmaceuticals, Inc. since early 1994 in which role he has management
responsibility for the Company's activities in the areas of: business
development, M&A, licensing, intellectual property and corporate law and
corporate communications. He also serves on the Boards of Directors of
Millennium BioTherapeutics, Inc., Millennium Predictive Medicine, Inc.
and Millennium Information, Inc., all majority-owned subsidiaries of
Millennium. Prior to joining Millennium, from 1986-1994, Mr. Holtzman
was a founder and the first employee of DNX Corporation (now known as
Chrysalis), a pioneer in the development of biomedical and
pharmaceutical applications of transgenic animal technology. At DNX, he
held several management positions, including Executive Vice President
and Member of the Executive Committee of the Board of Directors as well
as President of DNX Bio-Therapeutics, Inc., DNX's wholly-owned
biotechnology subsidiary (now Nextran, a subsidiary of Baxter
Healthcare). Prior to DNX, Mr. Holtzman conceived of and was the
founding Executive Director of the Ohio Edison Program, one of the
nation's first state government programs for funding young technology-
based ventures and university/industry collaborative research and
development efforts. Since 1995 Mr. Holtzman has been the Co-Chair of
the Biotechnology Industry Organization (BIO) Bioethics Committee and,
in 1996, was appointed by President Clinton to the National Bioethics
Advisory Commission. In 1998, he served as a member of the Working Group
of the Advisory Committee to the Director of the NIH on Access to
Research Tools. Mr. Holtzman received his B.A. in Philosophy from
Michigan State University and his B.Phil. graduate degree in Philosophy
from Oxford University which he attended as a Rhodes Scholar. Profile
Pharmaceuticals the company's history, activities, those kinds of
things, please.
Mr. Holtzman: Millennium was formed in
